Logo image of RLMD

RELMADA THERAPEUTICS INC (RLMD) Stock Analyst Ratings

NASDAQ:RLMD - US75955J4022 - Common Stock

0.627 USD
+0.02 (+2.79%)
Last: 8/22/2025, 8:00:02 PM
0.627 USD
0 (0%)
Pre-Market: 8/25/2025, 4:05:02 AM
Buy % Consensus

46

ChartMill assigns a Buy % Consensus number of 46% to RLMD. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 0.88. This target is 40.99% above the current price.
RLMD was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about RLMD.
In the previous month the buy percentage consensus was at a similar level.
RLMD was analyzed by 7 analysts. More opinions would make the average more meaningful.

Related screens

RLMD Historical Analyst RatingsRLMD Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -71 -64 -57 -50 -43 -36 -29 -22 -15 -8 -1 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 0.630.611.020.881.05 - -3.35% 62.68% 40.99% 67.46%

Related screens

RLMD Current Analyst RatingRLMD Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0
Up and Down Grades
Date Firm Action Rating
2024-12-05 Mizuho Downgrade Outperform -> Neutral
2024-12-04 Leerink Partners Downgrade Outperform -> Market Perform
2024-09-17 Jefferies Upgrade Hold -> Buy
2024-06-05 Goldman Sachs Downgrade Neutral -> Sell
2023-06-15 Mizuho Reiterate Buy -> Buy
2023-01-23 SVB Leerink Maintains Outperform
2022-10-14 Guggenheim Downgrade Buy -> Neutral
2022-10-14 Goldman Sachs Downgrade Buy -> Neutral
2022-10-13 Oppenheimer Downgrade Outperform -> Perform
2022-09-23 Goldman Sachs Maintains Buy
2022-09-06 Guggenheim Maintains Buy
2022-05-09 Oppenheimer Maintains Outperform
2021-12-20 SVB Leerink Maintains Outperform
2021-11-18 Mizuho Initiate Buy